Millipore Acquires NovAseptic AB: Broadens Offering to Biotech and Pharmaceutical Industry
Millipore Corporation announced that it has completed the acquisition of over 90% of the shares of NovAseptic AB from the company's majority shareholders. Millipore is in the process of acquiring the remaining shares from the minority shareholders.
Martin Madaus, Millipore's Chairman, CEO and President, noted: "NovAseptic brings innovative and differentiated products that our biotech and pharmaceutical customers value highly for manufacturing biologics and for monitoring bio-manufacturing processes. There is a great fit strategically and tactically, and we've added exceptional technology and talent to Millipore."
NovAseptic, based in Gothenburg, Sweden, provides a range of innovative solutions for aseptic processing applications in biotech and pharmaceutical manufacturing operations. NovAseptic's products include a unique disposable sampling system (NovaSeptum(R)) and a range of high-performance mixers, valves, and connectors.
Other news from the department business & finance
These products might interest you

2mag Magnetic Stirrers Catalogue 2024 by 2mag
Wear-free magnetic stirrers for laboratory and cell culture
Request the 2mag catalogue 2024 with innovative stirring solutions now

YSTRAL Conti-TDS by ystral
YSTRAL Conti-TDS: The No. 1 in Powder Wetting
Induct, wet and disperse powder

Drive Units for Pro Mixer by Sartorius
Magnetic disposable agitator without surface contact perfect for biopharmaceutical process
Improved efficiency in cell harvesting and buffer preparation through advanced technology

Flexsafe® Bag for Pro Mixer without top port - 1500 L by Sartorius
Efficient bioprocess optimisation: 1500 L Flexsafe® Pro Mixer Bag
Improved mixing processes and easy handling thanks to ergonomic design and inline sensors

Innovative Magnetic Stirrers by 2mag
Magnetic stirrer of the future - for laboratories and pilot plants
Individually configurable, 100 % wear-free, 3-year guarantee

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Evotec and Celgene collaborate in drug discovery for neurogenerative diseases
Evotec and Roche Form Global Alliance to Jointly Discover Novel Drugs

Oral vaccine instead of injections? - Exotic workers help with mRNA vaccination through the stomach
Learning how the brain takes out its trash
Newly discovered plant enzyme could lead to more efficient ethanol production from cellulose

Multifunctional catalyst for poison-resistant hydrogen fuel cells
Biotage acquires ATDBio - Biotage strengthens its position in DNA and RNA Oligonucleotide synthesis and purification
Graffinity and Elan launch fragment-based drug discovery collaboration

Q1 Results: Merck Benefits from Global Diversification in a Challenging Environment - Medium-term structural growth drivers intact

Immune Cells Shape their own Path - Scientists show how immune cells migrate along self-generated gradients
Life Science Labs Reacting to the Economic Crisis
